Dry eye disease and inflammation
In the 12-week OPUS-3 trial, lifitegrast reduced eye-dryness symptoms more than placebo. A difference appeared by day 14, although not every secondary measure changed consistently.
doi: 10.1016/j.ophtha.2016.09.025The study assessed specialist nursing support within a chronic-disease management pathway.
doi: 10.1097/SCS.0000000000012254The analysis examined baseline features associated with response in evaporative dry eye.
doi: 10.1097/ICO.0000000000003927A systematic review examined endpoints used in dry-eye clinical studies.
doi: 10.1111/aos.70031Two phase 3 trials compared acoltremon with vehicle for signs and symptoms of dry eye.
doi: 10.1016/j.ophtha.2025.09.018A post-hoc analysis focused on patients with moderate-to-severe corneal staining in randomised trials.
doi: 10.1007/s00417-025-07054-7